Here is the design of a clinical trial:

Official Title: Effects of Berberine Plus Inulin on Diabetes Care in Patients With Latent Autoimmune Diabetes in Adults: A Randomized Controlled Trial

Included conditions:
- Type 1 Diabetes Mellitus
- Autoimmune Diabetes

Study Armgroups:
- {'label': 'Group A', 'type': 'EXPERIMENTAL', 'description': 'LADA patients are assigned to receive berberine and inulin for 3-month.', 'interventionNames': ['Drug: Berberine', 'Drug: Inulin']}
- {'label': 'Group B', 'type': 'EXPERIMENTAL', 'description': 'LADA patients are assigned to receive berberine and placebo(for inulin) for 3-month.', 'interventionNames': ['Drug: Berberine', 'Drug: Inulin placebo tablets']}
- {'label': 'Group C', 'type': 'EXPERIMENTAL', 'description': 'LADA patients are assigned to receive placebo(for berberine) and inulin for 3-month.', 'interventionNames': ['Drug: Inulin', 'Drug: Berberine placebo tablets']}
- {'label': 'Group D', 'type': 'PLACEBO_COMPARATOR', 'description': 'LADA patients are assigned to receive placebo(for berberine) and placebo(for inulin) for 3-month.', 'interventionNames': ['Drug: Berberine placebo tablets', 'Drug: Inulin placebo tablets']}

Interventions:
- {'type': 'DRUG', 'name': 'Berberine', 'description': '0.6g (6 pills) of Berberine tablets administered twice a day orally before meal for 3 months', 'armGroupLabels': ['Group A', 'Group B']}
- {'type': 'DRUG', 'name': 'Inulin', 'description': '0.6g (6 pills) of Inulin tablets administered twice a day orally before meal for 3 months', 'armGroupLabels': ['Group A', 'Group C']}
- {'type': 'DRUG', 'name': 'Berberine placebo tablets', 'description': '0.6g (6 pills) of Berberine placebo tablets administered twice a day orally before meal for 3 months', 'armGroupLabels': ['Group C', 'Group D']}
- {'type': 'DRUG', 'name': 'Inulin placebo tablets', 'description': '0.6g (6 pills) of Inulin placebo tablets administered twice a day orally before meal for 3 months', 'armGroupLabels': ['Group B', 'Group D']}

Primary Outcomes:
- {'measure': 'Change in HbA1c', 'description': 'The primary outcome measure is the change in mean HbA1c level, reflecting the blood glucose management status of the patients.', 'timeFrame': '1 year after start of trial'}

Please estimate the sample size based on the assumption: 
A two-sided alpha level of 0.05, 80% power, and consideration of reasonable attrition.
2.1.2 Sample Size Determination
          Sample size was determined using published data from a 12-week clinical trial with BBR and probiotics, in which the drugs decreased HbA1c by 0.44% in people with T2D (Zhang, Gu etÂ al., 2020), assuming a common within-group standard deviation (SD) of 0.80% and a two-sided Î± level of 0.05. With these assumptions, a sample size of 53 evaluable subjects per arm provided 80% power to detect a difference from placebo. Considering the reasonable attrition during the study, we planned to enroll 60 patients per group (i.e., a total of 240 patients).